<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="In-Process" Owner="NLM">
      <PMID Version="1">35379762</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1526-632X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>98</Volume>
            <Issue>21</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>24</Day>
            </PubDate>
          </JournalIssue>
          <Title>Neurology</Title>
          <ISOAbbreviation>Neurology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.</ArticleTitle>
        <Pagination>
          <StartPage>e2120</StartPage>
          <EndPage>e2131</EndPage>
          <MedlinePgn>e2120-e2131</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000200258</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND AND OBJECTIVES" NlmCategory="OBJECTIVE">To investigate the potential of plasma neurofilament light (pNfL) as a biomarker of disease progression and treatment response in progressive multiple sclerosis (PMS) with and without acute disease activity.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">A post hoc blinded analysis of pNfL levels in 2 placebo-controlled, phase 3 studies in secondary progressive multiple sclerosis (SPMS; EXPAND) and primary progressive multiple sclerosis (PPMS; INFORMS) using siponimod and fingolimod, respectively, as active compounds was performed. pNfL levels were quantified using a single molecule array (Homebrew Simoa) immunoassay from stored ethylenediaminetetraacetic acid (EDTA) plasma samples of all patients who consented for exploratory biomarker analysis in either study; pNfL levels were divided into high (≥30 pg/mL) and low (&lt;30 pg/mL) at baseline. We investigated the association of pNfL levels with disability progression, cognitive decline, and brain atrophy and their sensitivity to indicate treatment response through clinical measures.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">We analyzed pNfL in 4,185 samples from 1,452 patients with SPMS and 1,172 samples from 378 patients with PPMS. Baseline pNfL levels were higher in SPMS (geomean 32.1 pg/mL) than in PPMS (22.0 pg/mL; <i>p</i> &lt; 0.0001). In both studies, higher baseline pNfL levels were associated with older age, higher Expanded Disability Status Scale score, more Gd<sup>+</sup> lesions, and higher T2 lesion load (all <i>p</i> &lt; 0.05). Independent of treatment, high vs low baseline pNfL levels were associated with significantly higher risks of confirmed 3-month (SPMS [32%], hazard ratio [95% CI] 1.32 [1.09-1.61]; PPMS [49%], 1.49 [1.05-2.12]) and 6-month disability progression (SPMS [26%], 1.26 [1.01-1.57]; PPMS [48%], 1.48 [1.01-2.17]), earlier wheelchair dependence (SPMS [50%], 1.50 [0.96-2.34]; PPMS [197%], 2.97 [1.44-6.10]), cognitive decline (SPMS [41%], 1.41 [1.09-1.84]), and higher rates of brain atrophy (mean change at month 24: SPMS, -0.92; PPMS, -1.39). Baseline pNfL levels were associated with future disability progression and the degree of brain atrophy regardless of presence or absence of acute disease activity (gadolinium-enhancing lesions or recent occurrence of relapses before baseline). pNfL levels were lower in patients treated with siponimod or fingolimod vs placebo-treated patients and higher in those having experienced disability progression.</AbstractText>
          <AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">pNfL was associated with future clinical and radiologic disability progression features at the group level. pNfL was reduced by treatment and may be a meaningful outcome measure in PMS studies.</AbstractText>
          <AbstractText Label="TRIAL REGISTRATION INFORMATION" NlmCategory="UNASSIGNED">EXPAND (ClinicalTrials.gov identifier: NCT01665144) and INFORMS (ClinicalTrials.gov identifier: NCT00731692).</AbstractText>
          <CopyrightInformation>© 2022 American Academy of Neurology.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Leppert</LastName>
            <ForeName>David</ForeName>
            <Initials>D</Initials>
            <Identifier Source="ORCID">0000-0001-6172-801X</Identifier>
            <AffiliationInfo>
              <Affiliation>From the Neurologic Clinic and Policlinic (D.L., L.K., J.K.), MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital and University of Basel; Novartis Pharma AG (H.K., D.A.H., F.D., D.T.), Basel, Switzerland; Novartis Healthcare Pvt. Ltd. (A.P.), Hyderabad, India; and DATAMAP GmbH (R.M.), Freiburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kropshofer</LastName>
            <ForeName>Harald</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>From the Neurologic Clinic and Policlinic (D.L., L.K., J.K.), MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital and University of Basel; Novartis Pharma AG (H.K., D.A.H., F.D., D.T.), Basel, Switzerland; Novartis Healthcare Pvt. Ltd. (A.P.), Hyderabad, India; and DATAMAP GmbH (R.M.), Freiburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Häring</LastName>
            <ForeName>Dieter A</ForeName>
            <Initials>DA</Initials>
            <Identifier Source="ORCID">0000-0001-5690-8710</Identifier>
            <AffiliationInfo>
              <Affiliation>From the Neurologic Clinic and Policlinic (D.L., L.K., J.K.), MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital and University of Basel; Novartis Pharma AG (H.K., D.A.H., F.D., D.T.), Basel, Switzerland; Novartis Healthcare Pvt. Ltd. (A.P.), Hyderabad, India; and DATAMAP GmbH (R.M.), Freiburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dahlke</LastName>
            <ForeName>Frank</ForeName>
            <Initials>F</Initials>
            <Identifier Source="ORCID">0000-0003-3333-6291</Identifier>
            <AffiliationInfo>
              <Affiliation>From the Neurologic Clinic and Policlinic (D.L., L.K., J.K.), MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital and University of Basel; Novartis Pharma AG (H.K., D.A.H., F.D., D.T.), Basel, Switzerland; Novartis Healthcare Pvt. Ltd. (A.P.), Hyderabad, India; and DATAMAP GmbH (R.M.), Freiburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Patil</LastName>
            <ForeName>Ashwini</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>From the Neurologic Clinic and Policlinic (D.L., L.K., J.K.), MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital and University of Basel; Novartis Pharma AG (H.K., D.A.H., F.D., D.T.), Basel, Switzerland; Novartis Healthcare Pvt. Ltd. (A.P.), Hyderabad, India; and DATAMAP GmbH (R.M.), Freiburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Meinert</LastName>
            <ForeName>Rolf</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>From the Neurologic Clinic and Policlinic (D.L., L.K., J.K.), MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital and University of Basel; Novartis Pharma AG (H.K., D.A.H., F.D., D.T.), Basel, Switzerland; Novartis Healthcare Pvt. Ltd. (A.P.), Hyderabad, India; and DATAMAP GmbH (R.M.), Freiburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tomic</LastName>
            <ForeName>Davorka</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>From the Neurologic Clinic and Policlinic (D.L., L.K., J.K.), MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital and University of Basel; Novartis Pharma AG (H.K., D.A.H., F.D., D.T.), Basel, Switzerland; Novartis Healthcare Pvt. Ltd. (A.P.), Hyderabad, India; and DATAMAP GmbH (R.M.), Freiburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kappos</LastName>
            <ForeName>Ludwig</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>From the Neurologic Clinic and Policlinic (D.L., L.K., J.K.), MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital and University of Basel; Novartis Pharma AG (H.K., D.A.H., F.D., D.T.), Basel, Switzerland; Novartis Healthcare Pvt. Ltd. (A.P.), Hyderabad, India; and DATAMAP GmbH (R.M.), Freiburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kuhle</LastName>
            <ForeName>Jens</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>From the Neurologic Clinic and Policlinic (D.L., L.K., J.K.), MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital and University of Basel; Novartis Pharma AG (H.K., D.A.H., F.D., D.T.), Basel, Switzerland; Novartis Healthcare Pvt. Ltd. (A.P.), Hyderabad, India; and DATAMAP GmbH (R.M.), Freiburg, Germany. jens.kuhle@usb.ch.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT01665144</AccessionNumber>
              <AccessionNumber>NCT00731692</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>04</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Neurology</MedlineTA>
        <NlmUniqueID>0401060</NlmUniqueID>
        <ISSNLinking>0028-3878</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>5</Day>
          <Hour>5</Hour>
          <Minute>31</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35379762</ArticleId>
        <ArticleId IdType="doi">10.1212/WNL.0000000000200258</ArticleId>
        <ArticleId IdType="pii">WNL.0000000000200258</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
